Suppr超能文献

2019 新型冠状病毒患者凝血因子的作用:系统评价和荟萃分析。

The effect of coagulation factors in 2019 novel coronavirus patients: A systematic review and meta-analysis.

机构信息

Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital Fudan University, Shanghai, China.

出版信息

Medicine (Baltimore). 2021 Feb 19;100(7):e24537. doi: 10.1097/MD.0000000000024537.

Abstract

BACKGROUND

The role of coagulation dysfunction in Severe Coronavirus Disease 2019 (COVID-19) is inconsistent. We aimed to explore the impact of coagulation dysfunction amongst patients with COVID-19.

METHODS

We searched PubMed, Cochrane and Embase databases from December 1, 2019 to April 27, 2020 following Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines. Data about coagulation (Platelets, PT, APTT, fibrin, fibrinogen degradation products, D-dimer), prevalence of coagulation dysfunction and mortality were extracted. Meta regression was used to explore the heterogeneity.

RESULTS

Sixteen observational studies were included, comprising 2, 139 patients with confirmed COVID-19. More severe COVID-19 cases tended to have higher mean D-dimer (SMD 0.78, 95% CI 0.53 to 1.03, P < .001). The similar pattern occurred with PT and fibrin, with a contrary trend for PLTs. Coagulation dysfunction was more frequent in severe cases compared to less severe (SMD 0.46, 95% CI 0.25 to 0.67, P < .001). Higher mortality was associated with COVID-19-related coagulopathy (RR 10.86, 2.86 to 41.24, P < .001). Prevalence of ARDS was increased in more severe patients than less severe cases (RR 16.52, 11.27 to 24.22, P < .001). PT, fibrin and D-dimer levels elevated significantly in non-survivors during hospitalization.

CONCLUSION

Presence of coagulation dysfunction might be associated with COVID-19 severity, and coagulopathy might be associated with mortality. Coagulation markers including PT, fibrin and D-dimer may imply the progression of COVID-19. This illuminates the necessity of effectively monitoring coagulation function for preventing COVID-19-related coagulopathy, especially in severe patients. For the obvious heterogeneity, the quality of the evidence is compromised. Future rigorous randomized controlled trials that assess the correlation between coagulation and COVID-19 are needed.

TRIAL REGISTRATION

PROSPERO (CRD42020183514).

摘要

背景

凝血功能障碍在严重的 2019 年冠状病毒病(COVID-19)中的作用并不一致。我们旨在探讨 COVID-19 患者凝血功能障碍的影响。

方法

我们根据流行病学观察性研究荟萃分析(MOOSE)指南,从 2019 年 12 月 1 日至 2020 年 4 月 27 日在 PubMed、Cochrane 和 Embase 数据库中进行检索。提取凝血(血小板、PT、APTT、纤维蛋白、纤维蛋白原降解产物、D-二聚体)、凝血功能障碍发生率和死亡率的数据。采用Meta 回归法探索异质性。

结果

纳入了 16 项观察性研究,共包含 22139 例确诊 COVID-19 患者。病情较重的 COVID-19 患者的平均 D-二聚体水平较高(SMD 0.78,95%CI 0.53 至 1.03,P<0.001)。PT 和纤维蛋白也出现类似的趋势,而 PLTs 则相反。与病情较轻的患者相比,病情较重的患者凝血功能障碍更为常见(SMD 0.46,95%CI 0.25 至 0.67,P<0.001)。COVID-19 相关凝血障碍与更高的死亡率相关(RR 10.86,2.86 至 41.24,P<0.001)。与病情较轻的患者相比,病情较重的患者发生 ARDS 的比例更高(RR 16.52,11.27 至 24.22,P<0.001)。住院期间,非幸存者的 PT、纤维蛋白和 D-二聚体水平显著升高。

结论

凝血功能障碍的存在可能与 COVID-19 的严重程度相关,凝血障碍可能与死亡率相关。PT、纤维蛋白和 D-二聚体等凝血标志物可能预示着 COVID-19 的进展。这表明有效监测凝血功能对于预防 COVID-19 相关凝血障碍,尤其是在重症患者中,是必要的。由于明显的异质性,证据质量受到影响。需要进行未来的严格随机对照试验,以评估凝血与 COVID-19 之间的相关性。

试验注册

PROSPERO(CRD42020183514)。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbe4/7899891/9f3ee09f1d9f/medi-100-e24537-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验